Trulieve Cannabis Corp. annual report, FY2024

Trulieve Cannabis Corp. 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing is the Annual Report on Form 10-K for Trulieve Cannabis Corp. for the fiscal year ended December 31, 2024. Trulieve is a vertically integrated, multi-state cannabis operator headquartered in Quincy, Florida. As of year-end, the company operated 225 dispensaries and 15 cultivation and processing facilities across nine U.S. states: Florida, Arizona, Pennsylvania, West Virginia, Georgia, Maryland, Ohio, Connecticut, and Colorado. The company is the largest cannabis retailer in the United States by store count.

Key Financial Metrics

Metric (in millions) 2024 2023
Revenue $1,186.5 $1,129.2
Gross Profit $715.7 $588.6
Gross Margin 60.3% 52.1%
Operating Income $97.8 ($221.6) Loss
Net Loss (GAAP) ($160.6) ($533.1)
Adjusted EBITDA (Non-GAAP) $420.2 $322.3
Operating Cash Flow $271.5 $201.8
Cash & Short-Term Investments $299.2 $201.4
Total Debt (Long-Term + Current) ~$602.1 ~$600.8

Note: Total Debt includes Private Placement Notes ($368.0M), Notes Payable ($117.1M), and Construction Finance Liabilities ($137.4M).

Material Changes vs. Prior Period

  • Revenue Growth: Revenue increased 5.1% to $1.19 billion, driven by a $45.3 million increase in retail revenue (due to 33 new stores and higher productivity) and a $12.0 million increase in wholesale revenue (primarily in Maryland and Pennsylvania).
  • Margin Expansion: Gross margin improved significantly from 52.1% to 60.3%, attributed to at-scale cost efficiencies in production and disciplined promotional activity. Cost of Goods Sold (COGS) decreased 12.9% despite revenue growth.
  • Expense Volatility: General and Administrative (G&A) expenses surged 73.1% to $252.7 million. This was primarily due to $117.5 million in legislative campaign contributions (compared to $20.1 million in 2023), alongside increased IT and compensation costs.
  • Profitability: The company returned to operating profitability ($97.8M income) compared to a $221.6M operating loss in 2023. This turnaround was aided by the absence of the $307.6 million goodwill impairment recorded in 2023.
  • Tax Provision: The provision for income taxes increased to $197.6 million (up 30.5%), driven by higher gross profit and a one-time revaluation of deferred taxes due to changes in state filing methods.

Guidance, Outlook, Risks, and Unusual Items

  • Regulatory Landscape: Cannabis remains a Schedule I controlled substance under U.S. federal law. The DEA's rescheduling process to Schedule III was paused indefinitely in January 2025 following an interlocutory appeal. The company notes that even if rescheduled, FDA regulation could impose new costs.
  • Tax Position (Section 280E): The company maintains a position that IRC Section 280E does not preclude the deduction of ordinary business expenses. Consequently, it recorded $445.2 million in uncertain tax position liabilities as of December 31, 2024, up from $180.4 million in 2023. This includes $412.6 million related to the Section 280E challenge.
  • Legislative Activity: Florida's Amendment 3 (adult-use legalization) failed in November 2024, falling short of the required 60% supermajority. A new initiative is planned for the 2026 ballot.
  • Internal Controls: The company successfully remediated material weaknesses in internal controls over financial reporting (ITGCs and inventory valuation) identified in 2023. The auditor issued an unqualified opinion on internal controls for 2024.
  • Management Change: On February 26, 2025, Jason Pernell was appointed as President of the Company.

Investor Verification Checklist

  • Tax Liability Exposure: Verify the sustainability of the company's tax position regarding IRC Section 280E and the potential impact of the $445.2 million uncertain tax liability on future cash flows.
  • Legislative Contributions: Assess the return on investment for the $117.5 million spent on legislative campaign contributions in 2024, particularly given the failure of the Florida adult-use ballot initiative.
  • Debt Covenants: Review compliance with financial covenants in the $368 million private placement notes and other debt instruments, specifically regarding indebtedness to EBITDA ratios.
  • Inventory Valuation: Confirm the methodology for inventory valuation (lower of cost or net realizable value) given the volatility in the cannabis market and the company's significant inventory balance of $231.4 million.
  • Regulatory Rescheduling: Monitor the status of the DEA's rescheduling proceedings and potential FDA regulatory requirements that could alter the cost structure of the business.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.